ImmunoGen Inc (IMGN)

[skitahoe]

I think you're right on the money. The FDA has a great deal of knowledge about MIRV, the Soraya trial was based on the guidance the FDA provided and it met the goals they established. Even a September approval is possible, though unlikely.

I believe the $8 target you set could be hit by mid-September, I believe that double digits will be seen post approval, and perhaps shortly before it.

Gary